Alphamab Oncology licenses overseas rights for cancer therapy to Pathos AI for $2.09 billion
04/08/2026 02:19
Alphamab Oncology licenses overseas rights for cancer therapy to Pathos AI for $2.09 billion Aug 4 (Reuters) - China-based biopharmaceutical company Alphamab Oncology 9966.HK said on Tuesday it had granted U.S.-based Pathos AI overseas rights to its experimental cancer therapy JSKN016 in a deal worth up to $2.09 billion.
JSKN016 is Alphamab's lead cancer drug candidate, currently in late-stage testing for triple-negative breast cancer and earlier-stage studies in other tumours.
(Reporting by Roshan Thomas in Bengaluru; Editing by Rashmi Aich)
Recent news on Alphamab Oncology
See all newsBrief: Alphamab Oncology Says Fei Wang Resigns As Chief Financial Officer
Brief: Alphamab Oncology Says First Patient Dosed In Phase III Clinical Study Of JSKN033 Monotherapy For Treatment Of Cervical Cancer
Brief: Alphamab Oncology Says Board Resolves To Repurchase Shares Up To HK$80 Million In Value
Brief: Alphamab Oncology Says NMPA Accepts NDA For Anbenitamab With HB1801 For Her2+ Advanced Breast Cancer
Brief: Alphamab Oncology Says NMPA Accepts NDA For Anbenitamab (KN026)